252 related articles for article (PubMed ID: 31166114)
1. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
[No Abstract] [Full Text] [Related]
2. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
3. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
Kook E; Lee J; Kim DH
Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
[TBL] [Abstract][Full Text] [Related]
4. YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
Takeda T; Yamamoto H; Suzawa K; Tomida S; Miyauchi S; Araki K; Nakata K; Miura A; Namba K; Shien K; Soh J; Shien T; Kitamura Y; Sendo T; Toyooka S
Cancer Sci; 2020 Mar; 111(3):849-856. PubMed ID: 31856375
[TBL] [Abstract][Full Text] [Related]
5. YES1 Is a Druggable Oncogenic Target in SCLC.
Redin E; Garrido-Martin EM; Valencia K; Redrado M; Solorzano JL; Carias R; Echepare M; Exposito F; Serrano D; Ferrer I; Nunez-Buiza A; Garmendia I; García-Pedrero JM; Gurpide A; Paz-Ares L; Politi K; Montuenga LM; Calvo A
J Thorac Oncol; 2022 Dec; 17(12):1387-1403. PubMed ID: 35988891
[TBL] [Abstract][Full Text] [Related]
6. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
[TBL] [Abstract][Full Text] [Related]
7. YES1: A Novel Therapeutic Target and Biomarker in Cancer.
Garmendia I; Redin E; Montuenga LM; Calvo A
Mol Cancer Ther; 2022 Sep; 21(9):1371-1380. PubMed ID: 35732509
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.
Chen B; Xu X; Luo J; Wang H; Zhou S
PLoS One; 2015; 10(6):e0129663. PubMed ID: 26061184
[TBL] [Abstract][Full Text] [Related]
9. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
Fujihara M; Shien T; Shien K; Suzawa K; Takeda T; Zhu Y; Mamori T; Otani Y; Yoshioka R; Uno M; Suzuki Y; Abe Y; Hatono M; Tsukioki T; Takahashi Y; Kochi M; Iwamoto T; Taira N; Doihara H; Toyooka S
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884609
[TBL] [Abstract][Full Text] [Related]
10. SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.
Sato H; Kubota D; Qiao H; Jungbluth A; Rekhtman N; Schoenfeld AJ; Yu HA; Riely GJ; Toyooka S; Lovly CM; Paik P; Ladanyi M; Fan PD
JCO Precis Oncol; 2022 Aug; 6():e2200088. PubMed ID: 35952318
[TBL] [Abstract][Full Text] [Related]
11. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
Yoshioka T; Shien K; Takeda T; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Soh J; Fujiwara T; Toyooka S
Cancer Sci; 2019 Aug; 110(8):2549-2557. PubMed ID: 31162771
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion.
Je DW; O YM; Ji YG; Cho Y; Lee DH
Pancreas; 2014 Jul; 43(5):768-76. PubMed ID: 24763074
[TBL] [Abstract][Full Text] [Related]
15. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
16. Identification of downstream signaling cascades of ACK1 and prognostic classifiers in non-small cell lung cancer.
Zhu J; Liu Y; Zhao M; Cao K; Ma J; Peng S
Aging (Albany NY); 2021 Jan; 13(3):4482-4502. PubMed ID: 33495411
[No Abstract] [Full Text] [Related]
17. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
19. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
20. A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo.
Ling C; Chen G; Chen G; Zhang Z; Cao B; Han K; Yin J; Chu A; Zhao Y; Mao X
Int J Cancer; 2012 Nov; 131(10):2411-9. PubMed ID: 22362357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
